Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids : a systematic review and meta-analysis by R.E. Rossi et al.
Review Article
Response and relapse rates after treatment
with long-acting somatostatin analogs
in multifocal or recurrent type-1 gastric
carcinoids: A systematic review and
meta-analysis
Roberta Elisa Rossi1, Pietro Invernizzi2, Vincenzo Mazzaferro1
and Sara Massironi3
Abstract
Background: Type-1 gastric neuroendocrine tumors represent a recurring disease and long-acting somatostatin
analogs can inhibit both gastrin release and endocrine cell proliferation. The efficacy and timing of this treatment
are still unclear. We performed a systematic review of the literature to clarify the role of somatostatin analog
treatment in type-1 gastric neuroendocrine tumors.
Methods: A computerized literature search was performed using relevant keywords to identify all the pertinent
articles published in the last 15 years.
Results: Eight studies were included in this systematic review on somatostatin analogs in type-1 gastric neuroen-
docrine tumors. A complete response rate ranged from 25–100%. When only the six prospective studies were
considered, no significant heterogeneity was observed, and the pooled cumulative complete response rate was
84.5% (confidence interval 73.8–92.8). Three studies evaluated the type-1 gastric neuroendocrine tumor recurrence,
with a cumulative relapse rate of 30.2% (confidence interval 13.1–50.6) after 34 months.
Conclusion: Somatostatin analogs, namely lanreotide and octreotide, have an excellent response rate, with a good
safety profile in selected type-1 gastric neuroendocrine tumors, which cannot be safely managed by endoscopic
follow-up or resection due to multiple or frequently recurring disease. After therapy discontinuation, the cumulative
relapse rate observed after a median 34-month follow-up was relatively high (30.2%).
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Introduction
Gastric carcinoids or gastric neuroendocrine tumors
(gNETs) account for 8.7–23% of all digestive neuroen-
docrine neoplasms (NENs).1–3 Their incidence has
shown a 7–10-fold increase over the past few dec-
ades.4–8 Type-1 gNETs (gNET-1s), the most common
NETs of the stomach,9 are associated with chronic
autoimmune atrophic gastritis and hypergastrinemia.
Hypergastrinemia, which is the result of atrophic gastri-
tis, has been shown to stimulate the growth of epithelial
cells and prevent apoptosis, possibly contributing to
increased cancer risk, including type 1 gastric
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carcinoids.10 Furthermore, gNET-1 might also develop
as a result of hypergastrinemia due to long-standing
Helicobacter Pylori-related atrophic body gastritis.
gNET-1, which are more common in women and tend
to occur after the fifth decade of life,11–13 are mainly
benign; metastatic forms are rarely reported.14–18 A
tumor size> 10mm is proposed by European
NeuroEndocrine Tumor Society (ENETS) guidelines as
the cut-off diameter to identify tumors with more aggres-
sive behavior that deserve radical resection and/or a more
intensive follow-up program.3 In a recent multicenter
Italian study, including 156 gNETs, a tumor size
>10mm was significantly associated with potentially
malignant tumor behavior, irrespective of Ki67.19
The clinical management and treatment of gNET-1s
are a matter of debate as they are relatively benign
lesions,9,12,20 therefore minimally invasive procedures
are warranted. Small (1 cm) localized tumors should
be endoscopically resected.3,21–24 With larger lesions,
endoscopic mucosal resection or endoscopic submuco-
sal dissection (ESD) can be used to maximize complete
endoscopic resection rates,3,20,23,25 if there is no muscu-
laris propria invasion.20,26–28 Surgical resection is gen-
erally recommended in the case of involvement of the
muscularis propria and/or local lymph nodes docu-
mented by ultrasound endoscopy.3,20,26
However, gNET-1s often represent a multifocal and
recurring disease and, in cases of multiple (6 lesions),
recurrent, partially invasive (beyond submucosa),
> 2 cm sized tumors, guidelines are lacking and not as
univocal. In addition, the cut-off of six tumors pro-
posed by ENETS is not clearly based on solid scientific
evidence. Antrectomy has been suggested to achieve
gastrin suppression;3,29 however, data are scanty30
and recurrence might still happen.31,32 Therefore,
antrectomy plays a negligible role and seems no
longer justified, especially considering the risk of sur-
gery and the potential risk of developing adenocarcin-
oma in the remaining gastric mucosa.
Long-acting somatostatin analogs (SSAs) can be
used to both inhibit gastrin release and directly inhibit
endocrine cell proliferation.6,9,19,33–40 SSA therapy can
reduce and even normalize the gastrin and chromogra-
nin A (CgA) levels as well as induce regression of
gNET-1,19,41,42 thus represent a valid therapeutic
option. A high recurrence rate after the end of treat-
ment has been reported,20 which makes the efficacy of
this treatment questionable. Whether treatment should
be continued in the long term36,39 or discontinued after
1 year33–35,37,38 is unclear.
We performed a systematic review of the literature to
clarify the role of SSA treatment in complex cases of
gNET-1 and define its perfect timing.
Methods
A computerized literature search was performed in
PubMed, Embase, SCOPUS, and Web of Science
using both free language words and phrases and med-
ical subject heading terms including: gastric carcinoids
type 1; gastric neuroendocrine tumors; gastric neuroen-
docrine neoplasm; chronic atrophic gastritis; somato-
statin analogs; treatment; therapy; follow-up, with
the search strategy updated last on March 2019. For
‘‘disease condition’’, the following terms were used:
(gastric) AND (neuroendocrine OR endocrine) AND
(tumor OR tumour OR neoplasm) OR (carcinoid).
The search also included the following terms for
‘‘therapy’’: lanreotide OR octreotide OR somatostatin
AND analogs OR analogues. The reference lists from
the studies selected by the electronic search were then
manually searched to identify further relevant reports.
All the available primary studies, review articles,
abstracts and proceedings of relevant meetings were
considered, whereas non-English language papers
were excluded. The studies considered potentially eli-
gible were retrieved as full text and evaluated.
Disagreements were resolved by consensus.
Study selection criteria
Eligible studies investigated the use of octreotide or
lanreotide in patients with histologically confirmed
gNENs and clearly classified as gNET-1s. Both retro-
spective and prospective studies were included; single-
arm studies were also eligible. Indications to start
SSA therapy had to be clearly specified, due to multi-
focal disease (6 lesions), invasive (beyond sub-
mucosa),> 2 cm-sized tumors or recurrent disease.
The dosage and type of SSAs had to be specified and
studies in which SSAs were used at no standard dose
were excluded. A minimum of 12 months of follow-up
after therapy discontinuation was considered adequate.
Follow-up was defined as the time between the end of
treatment and the time of the last observation. In this
phase, both a possible recurrence of the gNET-1 and
any possible treatment side effects were monitored.
Assessment of the quality of the studies
All the studies included were evaluated for their meth-
odological quality, considering their study design
(cohort studies or case series), patient selection (con-
secutive or non-consecutive), data collection (prospect-
ive, retrospective or unknown), spectrum composition
(reflecting, or not, the representativeness of the patients
of the clinical practice), according with previously
defined standards.43,44
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Outcome measures
The primary endpoints were both the response rate and
recurrence-free survival to evaluate the efficacy of SSAs
in the treatment of ‘‘high risk’’ gNET-1. Secondary
endpoints were biochemical response and toxicity of
SSAs to establish the SSA treatment safety.
Methods of the review of the literature
Two reviewers (SM and RER) evaluated all the studies
identified as described above: each paper was re-
examined to confirm those fulfilling the inclusion cri-
teria and then graded on their methodological quality,
based on previously reported criteria.43,44 The data
concerning the types of participants and outcome meas-
ures were independently extracted by the reviewers,
who openly discussed any discrepancies. Only in the
case of disagreement was the further and definitive
judgment of an independent clinical expert (PI) applied.
The excluded studies and the reasons for exclusion
were recorded. In the case of duplicate publications, the
most up-to-date version was considered.
Statistical analysis
Demographic characteristics, complete response rates
and relapse rates were taken from each study and
exact 95% confidence intervals (CI) were calculated
based on a binomial distribution. Given the poor meth-
odological quality of most of the papers retrieved,
a more conservative model of random effects to pool
the estimates of outcome measures was used, even when
there was no significant heterogeneity.45 To test the
inconsistency of the study results, the I2 statistic was
used, indicating the percentage of variation among stu-
dies due to heterogeneity rather than chance. A meta-
analysis was performed only in the case of no statistical
heterogeneity among studies. All the statistical analyses
were performed by using MedCalc for Windows, ver-
sion 15.0 (MedCalc Software, Ostend, Belgium).
Results
A total of 1994 studies were identified. After filtering
for English language, human studies, year range, article
type, and removing duplicates, 31 articles were con-
sidered. Out of these, only eight studies18,33–35,37,39,40,46
fulfilled inclusion criteria for the current systematic
review as containing pertinent data. No randomized
clinical trials were found; therefore, a meta-analysis of
nonrandomized studies was done. Figure 1 represents
the study selection process in the PRISMA diagram.
Eight studies were included in the current systematic
review, with a total number of 117 patients studied
(Table 1). None of the studies were sponsored by any
organization. Six studies were prospective33–35,37,39,46
and two retrospective.18,40 Four studies34,35,37,39 inves-
tigated octreotide, three involved both lanreotide and
octreotide,33,40,46 whereas the type of SSA was not spe-
cified in one study only.18 The SSA used and the dosage
applied also varied among the studies. Doses used for
octreotide ranged from 20mg to 30mg over 28 days; in
the three studies using lanreotide, the doses utilized
ranged from 60mg to 120mg over 4 weeks.33,40,46
Considering all the studies, a complete response rate
after 12 months on SSA therapy ranged from 25% to
100%. No meta-analysis was performed because of the
significant heterogeneity of the studies. The study with
the highest response rate39 only included three patients,
and thus this response rate should be interpreted with
caution. The larger retrospective study was Italian
and multicenter by Campana et al.40 that included 97
gNET-1s, for which 36 patients were treated with SSAs.
SSA therapy resulted in a complete response for 76% of
patients and in stable disease for 24%. A prolonged
period of therapy (17 months or longer), the use of
a full dose of SSAs (lanreotide Autogel 120mg or
octreotide LAR 30mg every 28 days) and higher gastrin
levels at diagnosis were related to a complete response
to therapy. The larger prospective study was by
Grozinsky-Glasberg et al.,33 including 15 patients
with gNET-1 treated with monthly long-acting release
octreotide (20–30mg; n¼ 14) or lanreotide 90mg
(n¼ 1) for at least 6 months, in which the authors
reported a complete tumor disappearance at 1 year of
treatment in 11 patients (73%), whereas in three
patients (20%), the tumors decreased significantly in
number and size.
When only the six prospective studies (49 patients)
were considered, no significant heterogeneity was
observed, thus they were pooled in the final meta-ana-
lysis and the cumulative complete response rate was
84.5% (95% CI 73.8–92.8) (Figure 2).
In terms of treatment duration, no clear-cut data are
available. The majority of authors have suggested a
treatment period of at least 12 months.33–35,39,46
Three studies37,39,46 evaluated the relapse rate. No
significant statistical heterogeneity was observed and
from the meta-analysis performed, a cumulative relapse
rate of 30.2% (95% CI 13.1–50.6) after 34 months was
observed (Figure 3). A small Norwegian prospective
study by Jianu et al.37 analyzed the macroscopic and
histopathological changes in the stomach of five gNET-
1 patients 5 years after discontinuation of octreotide
previously taken for 1 year. The authors reported
that the disease had progressed in all five gNET-1
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Figure 1. Flowchart of the study selection process.
Table 1. Summary of the results of the eight studies evaluating SSAs in gNEN-1 and included in the systematic review.
Author Year
Type of
study
No.
pts gNEN-1 Intervention Schedule
Complete
response
at 12m (%)
Follow
up (m)
Recurrence
(%)
Massironi46 2015 Pros 12 Recurrent
gNEN-1
Octreo 30mg i.m.,
lanreo 120mg i.m.
every 28 days
For 12m
92 46.5 33 at 20m
Khuroo39 2010 Pros 3 gNEN-1 Octreo 20mg i.m. every 28 days
For 12m
100 34 0 at 34m
Grosinski33 2008 Pros 15 gNEN-1 Octreo 20/30mg i.m. every 28 days
Long-term
73 18 NA
Campana34 2008 Pros 9 Multiple
gNEN-1> 5mm
Octreo 30mg i.m. every 28 days
For 12m
100 12 NA
Fykse35 2004 Pros 5 gNEN-1 Octreo 20mg i.m. every 28 days
For 12m
80 12 NA
Jianu37 2011 Pros 5 gNEN-1 Octreo 20mg i.m. every 28 days
For 12m
80 84 40 at 60m
Thomas18 2013 Retro 32 gNEN (G1-2)
Type not specified
SSA not further
specified
NA 25 39.5 NA
Campana40 2016 Retro 36 gNEN (G1-2)
Type not specified
Octreo 30/20mg or
lanreo 60/120mg
every 28 days
long term
76 NA NA
i.m.: intramuscular; gNEN1: gastric neuroendocrine neoplasm type 1; lanreo: lanreotide; octreo: octreotide; pros: prospective; retro: retrospect-
ive; SSA: somatostatin analog.
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patients: one patient had a highly malignant gastric
tumor, one had an increased number of gNET-1 with
regional and distant metastases, and three had an
increased number of gNET-1s.
For the adverse events rate, the rates of toxicity were
reported in seven studies.18,33–35,37,39,46 Considering the
prospective studies, this ranged from nil to 88%,
because of the different attention paid to adverse
events. In the study reporting 88% of adverse events,
intestinal bloating was the main symptom reported
in eight out of nine patients,34 but when considering
clinically significant adverse events, the rate varies
from 2% to 8%, thus confirming the safety profile
of the SSAs. The most common toxicities were
abdominal discomfort,34 cholelithiasis,46 diarrhea35,37
and fatigue or weight loss.35
Biochemical response rates were reported in six
studies18,33–35,39,46 in which a reduction in both circulat-
ing CgA and gastrin levels was observed. The extent of
the reduction was greater than 50% of the baseline
values in all the studies in which it was evaluated, there-
fore among these studies, the biochemical response
was observed in 100% of cases. The remaining two
studies did not report any information about biochem-
ical data.37,40
Discussion
According to the present study, in selected cases that
cannot be safely managed by endoscopic follow-up
or resection due to multiple or frequently recurring dis-
ease, SSAs have shown an excellent response rate (i.e. a
cumulative complete response rate of 84.5% when con-
sidering the six prospective studies) after 12 months on
therapy, with a good safety profile.
The use of SSA therapy in gNET-1s is still a matter
of debate. Therapeutic strategies for gNET-1s are based
on risk stratification according to tumor size, lesion
number, stage, and grade.14,18,34,41,47 According to the
current guidelines from the ENETS, endoscopic man-
agement with lesion resection3 represents the gold
standard for gNET-1s that do not infiltrate the muscu-
laris propria and with no evidence of angioinvasion,
whereas surgery should be limited to cases of clearly
demonstrated invasion beyond the submucosa and/or
with metastases. In cases of multiple (6 lesions),
recurrent, partially invasive (beyond submucosa),
> 2 cm-sized tumors, guidelines are lacking and not so
univocal. Furthermore, the cut-off of six tumors pro-
posed by ENETS is not clearly based on solid scientific
evidence. The results of this meta-analysis can complete
these areas of uncertainty. In light of our results, far
from being the first-line therapy for gNET-1s, SSAs
may represent a valid option in those complex cases
that, due the disease being recurrent, multifocal, or
the polyps are fewer than six in number, an endoscopic
therapy is not feasible and the alternative treatment
remains the surgical resection of the lesions associated
with surgical antrectomy. In this specific patient setting,
the evidence obtained from our meta-analysis supports
the use of SSAs.
Once therapy was discontinued and after a median
34-month follow-up, the cumulative relapse rate
observed was relatively high (30.2%). Campana
et al.40 observed that in patients with gNET-1s at
stages 0–2A, a disease recurrence of 26.3% was
observed in patients treated with SSAs and in 26.2%
of patients treated with endoscopic resection, with no
Meta-analysis
Massironi 2015
Khuroo MS 2010
Grosinski 2008
Campana D 2008
Fykse V 2004*
Jianu 2011*
Total (fixed effects)
Total (random effects)
0.2 0.4 0.6 0.8
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1.0
Figure 2. Forest plot of the prospective studies considered
for the final meta-analysis in which the cumulative complete
response rate to somatostatin analogs (SSAs) was 84.5% (95%
confidence interval 73.8–92.8).
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Figure 3. Forest plot of the three studies that evaluated the
relapse rate, showing the cumulative relapse rate of 30.2%
(95% confidence interval 13.1–50.6) after 34 months.
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statistically significant difference in terms of disease-
free survival. Prolonged medical therapy (17 months
or longer) was reported to be the only predictor of dis-
ease recurrence.
Recurrence after presumed successful treatment is
common because hypergastrinemia and underlying
Enterochromaffin-like (ECL) cells hyperplastic or dys-
plastic changes persist, as high as 65% within a year
after initial endoscopic treatment.19,22 Additionally, the
recurrence rate is likely to be affected by the type of
endoscopic procedure used to remove the neoplastic
lesions,14,48 as confirmed by the lower recurrence rates
reported by Japanese studies, where the use of ESD is
more common compared to standard polypectomy.21
The surgical approach, either antrectomy to achieve
gastrin suppression or partial/total gastrectomy, was
more common in the past and probably represented
an over-treatment for this subset of relatively indolent
tumors, also considering both the risk of surgery as well
as the potential risk of developing adenocarcinoma in
the remaining mucosa. In the retrospective study by
Thomas et al.,18 a 65% complete response rate was
observed in surgically treated patients, which was
lower when compared to previous data.49 A few cases
of recurrence even after surgery have been reported.31
In multiple and recurrent disease, SSAs can be there-
fore a viable therapeutic option instead of antrectomy.
The rationale for the use of SSAs is based on the rela-
tively indolent nature of these tumors and the SSA
action of both inhibiting gastrin secretion from G
cells and exerting an anti-proliferative effect on the
ECL cells.26,46,47
Treatment is generally well tolerated, although
some adverse effects have been reported, including
abdominal pain with cramps, constipation, diarrhea,
steatorrhea, injection site irritation and local pain,
nausea and vomiting. Hypothyroidism, cholecystitis,
and cholelithiasis, acute pancreatitis, alopecia, acute
hepatitis, hyperbilirubinemia, hyperglycemia, hypo-
glycemia, and prolonged QT intervals are less
common but are still possible complications.50,51
The SSA good safety profile has been confirmed by
the present study, as no serious adverse events were
reported by the included studies, except for one
patient developing cholelithiasis.
The precise duration of SSA treatment has not yet
been defined and, considering the relative indolent
nature of these tumors, the length of treatment needs
to be balanced with costs and possible side effects
including the risk of cholelithiasis, diarrhea, abdominal
discomfort and diabetes. However, a longer duration
appears to be related to lower recurrence rates.40
Furthermore, the subgroup of gNET-1 patients that
would benefit most from SSA treatment needs greater
clarification. According to the current evidence, SSA
therapy can be considered for patients with multiple
and highly recurrent tumors that are not amenable
to surgical treatment,26 or even instead of surgery,
which is poorly justified in this kind of relatively indo-
lent tumor.
A possible limitation of the present study is that
this is a meta-analysis of nonrandomized studies
and the application of formal meta-analytic methods
has been controversial.45 One reason for this has been
that potential biases related to the extreme diversity
of study designs and populations in epidemiology
make the interpretation of simple summaries problem-
atic. Another possible limitation is the small number
of included studies, especially those evaluating the
relapse rate, of which there were only three.37,39,46
Moreover, the number of patients included in each
study was small and the required sample size was
not calculated. In addition, methodological issues
related specifically to meta-analysis, such as publica-
tion bias, could have a particular impact when combin-
ing the results of nonrandomized studies. In contrast,
no statistical heterogeneity among studies was
present when considering only the six prospective stu-
dies,33–35,37,39,46 which represents a point of strength
for our study.
In summary, SSA therapy can be considered a
viable option for gNET-1s, although in those selected
cases that cannot be safely managed by endoscopic
follow-up or resection due multiple or recurrent dis-
ease, as SSA therapy has shown an excellent response
rate with a good safety profile. Further prospective
studies are warranted to draw a more robust conclu-
sion, especially for the precise duration of treatment to
reduce the percentage rate of tumor recurrence. The
identification of specific prognostic markers that can
identify the subset of gNET-1 patients with more
aggressive features, thus deserving more radical treat-
ment, also needs to be addressed in future studies.
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